

Figure 1




Figure 2




Figure 3





Figure 4a:



	Peptide	Source protein
P^I_1	HGYENPTYK	APLP2
	ALRNQATMVQK	DGKZ
	FTAEFSSRY	FAF1
	GVLGTVVHGK	MTCH2
P^I_2	KTYTKSSHLK	KLF2
	VIYNEQMASK	METTL7A
	ASAAASGGLLK	VCPIP1
	RVYNTDPLKEK	WDR45L

Figure 4b:




Figure 4b cont.:


neg. control

Figure 4b cont.:




Figure 4b cont.:




Figure 4C:

C




Figure 5:




Figure 5 cont.:

C




d

Source protein	HLA class I	UPN	HLA class II	UPN
CA1	SYNPATAKEI	14	SVSYNPATAKEII	10
	SYNPATAKEII	14		
BCAT1	ILSKLTDIQY	17	ILSKLTDIQYGREE	8
	LSKLTDIQY	17		
ATP5L	EIIGKRGIIIGY	8	YVGEIIGKRGIIIGYDV	2
		13		
		14		
		17		

Figure 5 cont.:

e



	Peptide	Source protein	CD4+ T-cell response in AML
P_{II_1}	HRSFVDLSGHNLANPHP	CLSTN1	4/15 (26,7%)
P_{II_2}	SPNIVIALSGNKADLA	RAB5A	3/15 (20,0%)
P_{II_3}	TEGQFVDLTGNRLTYT	MBL2	2/15 /13,3%)

Figure 6

